Bibliographic Metadata

Title
Influence of aminobisphosphonates on the osteogenic potential of bone marrow stromal cells (BMSCs) isolated from osteoporotic hip fracture patients / by Richard A. Lindtner
Additional Titles
Influence of aminobisphosphonates on the osteogenic potential of bone marrow stromal cells (BMSCs) isolated from osteoporotic hip fracture patients
AuthorLindtner, Richard A.
Thesis advisorBlauth, Michael
Published2014
Description143, 10 Bl. : Ill., graph. Darst.
Institutional NoteInnsbruck, Med. Univ., Diss., 2014
Date of SubmissionApril 2014
LanguageEnglish
Document typeDissertation (PhD)
Keywords (DE)Aminobisphosphonate / Osteoporosis / Bone marrow stromal cell / Mineralization / Osteogenic differentiation / Osteopontin
Keywords (GND)Oberschenkelbruch / Osteoporose / Osteoblast / Knochenmarkzelle / Diphosphonate / Proliferation
Restriction-Information
 The Document is only available locally
Links
Reference
Classification
Abstract (English)

Introduction: Human bone marrow stromal cells (BMSCs) represent the precursor cells of bone-forming osteoblasts and have been shown to be functionally altered in age-related osteoporosis. The present study therefore sought to evaluate the effects of both aminobisphosphonate (amino-BP) in vitro and in vivo treatment on the osteogenic differentiation capacity and viability of human BMSCs obtained from aged female osteoporotic hip fracture patients. Methods: BMSCs were isolated from 7 osteoporotic patients without history of amino-BP medication and from 3 osteoporotic patients undergoing oral alendronate therapy. BMSCs were incubated in osteogenic and adipogenic medium supplemented with or without zoledronate (10 and 100 nM). The effect of amino-BP treatment on BMSC osteogenesis was assessed by qRT-PCR and Western blot analysis of known osteogenic markers. Mineralized matrix formation of differentiating BMSCs was quantified at days 14 and 21 of osteogenic induction using Alizarin Red S staining. Results: In vitro exposure to zoledronate during osteogenic differentiation significantly enhanced mineralization of differentiating BMSCs. Moreover, we could show that BMSCs from aged osteoporotic hip fracture patients undergoing oral alendronate therapy exhibited a greatly enhanced mineralization capacity as compared to BMSCs from osteoporotic controls not receiving amino-BP therapy. In vitro and in vivo treatment with amino- BPs had a marked inhibitory effect on secreted phosphoprotein 1 (SPP1) gene expression. Finally, loss-of-function studies confirmed that specific knockdown of SPP1 expression resulted in a marked increase in mineralization of osteoporotic BMSCs. Conlusion: The results presented within this thesis, provide evidence for an osteoanabolic effect of amino-BPs on osteoporotic BMSCs and implicate the amino- BP-induced downregulation of SPP1 as a possible mechanism of action.

Stats
The PDF-Document has been downloaded 0 times.